Share this video  

ASH 2022 | Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma

Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, discusses the results of an analysis of the iStopMM study (NCT03327597) which evaluated whether SARS-CoV-2 vaccination has an impact on the risk of progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. The study reported no evidence of MGUS progression after vaccination. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Celgene: Research Funding; Amgen: Research Funding.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter